Deflazacort (Emflaza)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Treatment of patients at least 5 years of age with Duchenne muscular dystrophy (DMD)

Patients must meet the following criteria for the indication(s) above:

  • Diagnosis of Duchenne muscular dystrophy
  • 5 years of age of older
  • Has tried prednisone but experience severe adverse events (i.e., Cushingoid appearance, obesity, behavioral abnormalities/psychiatric adverse events) that could not be managed

Dosing:

  • Approximately 0.9mg/kg/day once daily (round up to nearest possible dose when using tablets, or round up to nearest tenth of a mL when using suspension)
  • Concomitant moderate of strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil): reduce dose to 1/3 of usual dose
  • Avoid use with moderate or strong CYP3A4 inducers

Approval:

  • 1 year

Last review date: May 1, 2017

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar